Vertex Pharmaceuticals Incorporated · VRTX
As of the latest run, Vertex Pharmaceuticals Incorporated (VRTX) scores 57/100 overall — a decent but mixed profile. Its strongest dimension: risk control (82/100); the one that most warrants attention: valuation (33/100).
Three pillars judge the company (profitability, growth, financial health), three judge the stock (valuation, momentum, risk). The score is recomputed every day from Yahoo Finance market data — the one shown above reflects today's state.
The risk pillar comes in at 82/100 — volatility kept in check by market standards. Profitability comes in at 75/100 — above-average margins and return on capital. Momentum comes in at 60/100 — a well-oriented price trend.
The breakdown of each pillar — and a plain-English explanation of what it measures — is available in the full analysis, free and updated every day.
Valuation falls to 33/100 — a stretched price relative to the stock's own valuation history. Financial health falls to 44/100 — a balance sheet under strain, on debt or liquidity.
No score replaces your own judgment: Stock Analyzer is a tool for analysis and understanding, not investment advice.